Health Care & Life Sciences » Biotechnology | Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
Depreciation, Depletion & Amortization
105.70
442.80
1,691.00
3,831.00
4,601.00
4,582
Other Funds
-
-
-
38,364.00
-
66,793
Funds from Operations
28,184.70
88,437.40
184,247.00
350,880.00
280,048.00
237,867
Changes in Working Capital
178.30
699.00
21,345.00
8,439.00
14,646.00
2,847
Net Operating Cash Flow
28,006.40
87,738.30
162,902.00
342,441.00
265,402.00
240,714
Capital Expenditures
1,629.10
4,643.20
5,935.00
5,079.00
10,392.00
Purchase/Sale of Investments
68,584.40
91,942.00
383,537.00
55,056.00
298,167.00
Net Investing Cash Flow
70,213.60
96,585.20
389,472.00
60,135.00
287,775.00
Issuance/Reduction of Debt, Net
-
-
-
447,573.00
-
Net Financing Cash Flow
66,071.50
190,983.30
565,469.00
414,382.00
2,838.00
Net Change in Cash
32,148.50
6,659.70
12,719.00
10,933.00
26,338.00
Free Cash Flow
29,635.60
92,381.50
168,837.00
347,520.00
275,794.00
Change in Capital Stock
66,071.50
190,983.30
565,469.00
5,173.00
2,838.00
Exchange Rate Effect
0.00
-
376.00
873.00
1,127.00

About Intercept Pharmaceuticals

View Profile
Address
10 Hudson Yards
New York New York 10001
United States
Employees -
Website http://www.interceptpharma.com
Updated 07/08/2019
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.